Aug 25, 2025
TransMedics to Present at Upcoming September Investor Conferences
Aug 04, 2025
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
Aug 01, 2025
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 30, 2025
TransMedics Reports Second Quarter 2025 Financial Results
Jul 29, 2025
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference
May 20, 2025
TransMedics to Present at Upcoming June Investor Conferences
May 08, 2025
TransMedics Reports First Quarter 2025 Financial Results
Apr 24, 2025
TransMedics to Report First Quarter 2025 Financial Results on May 8, 2025
Apr 02, 2025
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 27, 2025
TransMedics Reports Fourth Quarter and Full Year 2024 Financial Results
Feb 18, 2025
TransMedics to Present at Upcoming March Investor Conferences
Feb 03, 2025
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 13, 2025
TransMedics Responds to Inaccurate and Misleading Claims in Recent Short-Seller Report
Dec 23, 2024
TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Dec 12, 2024
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 02, 2024
TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook
Nov 26, 2024
TransMedics to Host Investor & Analyst Day on December 10, 2024
Nov 19, 2024
TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Oct 29, 2024
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 28, 2024
TransMedics Reports Third Quarter 2024 Financial Results